Hypertension a Good Sign in Patients Receiving Sunitinib

VBCC - April 2011, Volume 2, No 2 - Genitourinary Cancers Symposium
Caroline Helwick

Suzanne George, MDSan Francisco, CA—For patients with gastrointestinal stromal tumors (GIST) being treated with sunitinib (Sutent), the development of hypertension during treatment was associated with a survival benefit, said Suzanne George, MD, Dana-Farber Cancer Institute, Boston, at the 2011 Gastrointestinal Cancers Symposium.

Hypertension appears to be a class effect of vascular endothelial growth factor (VEGF) signaling pathway inhibitors and has been proposed as a biomarker of clinical outcomes for these agents. Sunitinib is a multitargeted inhibitor of VEGF receptors and the other receptor tyrosine kinase approved for the treatment of GIST after failure with imatinib (Gleevec) treatment.

In patients receiving sunitinib for renal-cell carcinoma, the occurrence of hypertension was a significant predictor of efficacy. “Sunitinib-associated hypertension appeared to be correlated with improved clinical outcomes, which support the hypothesis that hypertension may be a biomarker for antitumor efficacy,” Dr George said.

Safety, Efficacy of Hypertension in GIST
The current study retrospectively explored the association between hypertension and outcomes in 2 prospective clinical trials of sunitinib in GIST. The efficacy analysis included 319 patients; the safety analysis included 1565 patients. Hypertension was defined as a maximum systolic blood pressure (BP) ≥140 mm Hg and diastolic BP ≥90 mm Hg.

The development of hypertension at any time during treatment was associated with improved clinical outcomes, Dr George reported.

In the final multivariate analysis, investigators analyzed outcomes separately, according to maximum diastolic and systolic BP. Median progression free survival and median overall survival were significantly improved with elevated systolic or diastolic BP (Table).

In all comparisons, the development of hypertension was associated with a highly significant 50% reduction in recurrence and death. The superiority of these clinical outcomes was not compromised by treatment with antihypertensive medications, Dr George said.

Hypertension-associated adverse events were rare, although patients with hypertension had a slightly greater frequency and severity of cardiovascular adverse events than those without hypertension. Treating hypertension in this patient population is necessary as in other populations.

In addition to finding hypertension as a marker for good outcomes in this patient population in terms of cancerrelated survival, Dr George said, “the message is that physicians should monitor for hypertension early in treatment, because its mean onset is 4 to 6 weeks, and if they see it, they need to treat it.”

Related Items
Can Some Patients with Multiple Sclerosis Stop Treatment?
Caroline Helwick
Web Exclusives published on August 30, 2017 in Multiple Sclerosis
Oral Ozanimod: A Safer Sphingosine-1-Phosphate Receptor Modulator?
Caroline Helwick
Web Exclusives published on June 26, 2017 in Multiple Sclerosis
Vitamin D Supplementation Shows Benefits in Multiple Sclerosis, but Questions Remain
Caroline Helwick
Web Exclusives published on March 31, 2017 in Multiple Sclerosis
Ocrelizumab Receives Breakthrough Therapy for Progressive Multiple Sclerosis
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Ozanimod Achieves Very Low Relapse Rate in MS
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Stem-Cell Transplantation Shows Promise in Multiple Sclerosis, but Major Concerns Remain
Caroline Helwick
VBCN - April 2016 Volume 3, No 1 published on May 3, 2016 in Multiple Sclerosis
Treatment of Psoriatic Arthritis Explored by Cost-Effectiveness
Caroline Helwick
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Psoriatic Arthritis
Treatment Outcomes and Cost Assessed for Systemic Lupus Erythematosus
Caroline Helwick
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Lupus
Ankylosing Spondylitis Treatment Costs Assessed
Caroline Helwick
VBCR - June 2015, Volume 4, No 3 published on June 29, 2015 in Ankylosing Spondylitis
ASSURE Trial: No Role for Adjuvant Sorafenib or Sunitinib in Locally Advanced Kidney Cancer
Phoebe Starr
VBCC - March 2015, Vol 6, No 2 published on March 18, 2015 in Genitourinary Cancers Symposium
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology